SG10202010156XA - Compositions and methods for making antibodies based on use of an expression-enhancing locus - Google Patents
Compositions and methods for making antibodies based on use of an expression-enhancing locusInfo
- Publication number
- SG10202010156XA SG10202010156XA SG10202010156XA SG10202010156XA SG10202010156XA SG 10202010156X A SG10202010156X A SG 10202010156XA SG 10202010156X A SG10202010156X A SG 10202010156XA SG 10202010156X A SG10202010156X A SG 10202010156XA SG 10202010156X A SG10202010156X A SG 10202010156XA
- Authority
- SG
- Singapore
- Prior art keywords
- expression
- compositions
- methods
- antibodies based
- making antibodies
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Analytical Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662325385P | 2016-04-20 | 2016-04-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10202010156XA true SG10202010156XA (en) | 2020-11-27 |
Family
ID=58701850
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202010156XA SG10202010156XA (en) | 2016-04-20 | 2017-04-20 | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
SG11201807881VA SG11201807881VA (en) | 2016-04-20 | 2017-04-20 | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201807881VA SG11201807881VA (en) | 2016-04-20 | 2017-04-20 | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
Country Status (15)
Country | Link |
---|---|
US (2) | US11530277B2 (ko) |
EP (1) | EP3445780A1 (ko) |
JP (2) | JP7134868B2 (ko) |
KR (2) | KR102474757B1 (ko) |
CN (2) | CN116004544A (ko) |
AR (1) | AR108295A1 (ko) |
AU (1) | AU2017253240B2 (ko) |
BR (1) | BR112018071285A2 (ko) |
CA (1) | CA3015371A1 (ko) |
EA (1) | EA201892137A1 (ko) |
IL (2) | IL262268B2 (ko) |
MX (1) | MX2018012866A (ko) |
SG (2) | SG10202010156XA (ko) |
TW (1) | TW201803981A (ko) |
WO (1) | WO2017184831A1 (ko) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3728309A2 (en) * | 2017-12-22 | 2020-10-28 | Genentech, Inc. | Targeted integration of nucleic acids |
WO2020034097A1 (en) * | 2018-08-14 | 2020-02-20 | Wuxi Biologics (Shanghai) Co., Ltd. | Transcriptional regulatory element and its use in enhancing the expression of exogenous protein |
KR102559149B1 (ko) * | 2018-10-26 | 2023-07-24 | 에프. 호프만-라 로슈 아게 | 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법 |
EP3980544A1 (en) * | 2018-12-21 | 2022-04-13 | F. Hoffmann-La Roche AG | Targeted integration of nucleic acids |
MX2021011837A (es) * | 2019-03-29 | 2021-10-22 | Hoffmann La Roche | Método para la generación de una célula que expresa el receptor neonatal de región de fragmento cristalizable (fcrn) mediante la integración dirigida de múltiples casetes de expresión en una organización definida. |
MX2021011903A (es) | 2019-04-02 | 2021-10-26 | Chugai Pharmaceutical Co Ltd | Método para introducir un gen extraño específico del objetivo. |
MX2021015538A (es) * | 2019-06-19 | 2022-02-10 | Hoffmann La Roche | Metodo para la generacion de una celula que expresa un anticuerpo biespecifico bivalente mediante la integracion dirigida de multiples casetes de expresion en una organizacion definida. |
EP3986928A1 (en) * | 2019-06-19 | 2022-04-27 | F. Hoffmann-La Roche AG | Method for the generation of a protein expressing cell by targeted integration using cre mrna |
CA3140192A1 (en) | 2019-06-19 | 2020-12-24 | Johannes Auer | Method for the generation of a multivalent, multispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
WO2020254352A1 (en) | 2019-06-19 | 2020-12-24 | F. Hoffmann-La Roche Ag | Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
CN113993887A (zh) * | 2019-06-19 | 2022-01-28 | 豪夫迈·罗氏有限公司 | 通过以限定的组织形式靶向整合多个表达盒来产生多价双特异性抗体表达细胞的方法 |
WO2023122246A1 (en) * | 2021-12-22 | 2023-06-29 | Genentech, Inc. | Multi-vector recombinase mediated cassette exchange |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US6800457B2 (en) | 1998-09-22 | 2004-10-05 | Bristol-Myers Squibb Company | Expression vectors containing hot spot for increased recombinant protein expression in transfected cells |
US7455988B2 (en) | 2002-05-29 | 2008-11-25 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
JP2006512061A (ja) | 2002-11-14 | 2006-04-13 | ジェネンテック・インコーポレーテッド | イントロン融合コンストラクトおよび高発現産生細胞系を選択するための使用方法 |
EP3623473A1 (en) | 2005-03-31 | 2020-03-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
PT1999154E (pt) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Domínios proteicos heterodiméricos modificados |
CN102585002A (zh) | 2006-06-02 | 2012-07-18 | 瑞泽恩制药公司 | 人il-6受体的高亲和力抗体 |
JP2010514416A (ja) | 2006-12-21 | 2010-05-06 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 新規な方法 |
US20080216185A1 (en) | 2007-01-19 | 2008-09-04 | Invitrogen Corporation | Compositions and Methods for Genetic Manipulation and Monitoring of Cell Lines |
ES2667863T3 (es) | 2007-03-29 | 2018-05-14 | Genmab A/S | Anticuerpos biespecíficos y métodos de producción de los mismos |
PL2150617T3 (pl) * | 2007-06-04 | 2015-04-30 | Regeneron Pharma | Wzmocniona ekspresja i regiony stabilności |
DK2235064T3 (en) | 2008-01-07 | 2016-01-11 | Amgen Inc | A process for the preparation of heterodimeric Fc molecules using electrostatic control effects |
KR101441437B1 (ko) | 2009-06-02 | 2014-09-25 | 리제너론 파마슈티칼스 인코포레이티드 | 푸코실화-결핍 세포 |
EP2445936A1 (en) | 2009-06-26 | 2012-05-02 | Regeneron Pharmaceuticals, Inc. | Readily isolated bispecific antibodies with native immunoglobulin format |
WO2011034605A2 (en) | 2009-09-16 | 2011-03-24 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
US9150663B2 (en) | 2010-04-20 | 2015-10-06 | Genmab A/S | Heterodimeric antibody Fc-containing proteins and methods for production thereof |
PT2606064E (pt) | 2010-08-16 | 2015-06-08 | Novimmune Sa | Processos para a geração de anticorpos poliespecíficos e polivalentes |
EP3865581A1 (en) | 2011-08-05 | 2021-08-18 | Regeneron Pharmaceuticals, Inc. | Humanized universal light chain mice |
TW201823460A (zh) | 2012-05-29 | 2018-07-01 | 美商再生元醫藥公司 | 生產細胞株增強子 |
EP2711428A1 (en) | 2012-09-21 | 2014-03-26 | Lonza Biologics plc. | Site-specific integration |
JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
TWI745610B (zh) | 2012-11-14 | 2021-11-11 | 美商再生元醫藥公司 | 重組細胞表面捕捉蛋白質 |
TWI635098B (zh) * | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
US20140308285A1 (en) | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
TWI670283B (zh) | 2013-12-23 | 2019-09-01 | 美商建南德克公司 | 抗體及使用方法 |
TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
MX2017005306A (es) | 2014-10-23 | 2018-01-09 | Regeneron Pharma | Novedosos sitios de integracion en celulas cho y usos de estos. |
EP3353212B1 (en) | 2015-09-23 | 2021-11-03 | Regeneron Pharmaceuticals, Inc. | Optimized anti-cd3 bispecific antibodies and uses thereof |
-
2017
- 2017-04-20 BR BR112018071285A patent/BR112018071285A2/pt not_active Application Discontinuation
- 2017-04-20 SG SG10202010156XA patent/SG10202010156XA/en unknown
- 2017-04-20 AR ARP170101018A patent/AR108295A1/es unknown
- 2017-04-20 KR KR1020217035334A patent/KR102474757B1/ko not_active Application Discontinuation
- 2017-04-20 IL IL262268A patent/IL262268B2/en unknown
- 2017-04-20 WO PCT/US2017/028552 patent/WO2017184831A1/en active Application Filing
- 2017-04-20 AU AU2017253240A patent/AU2017253240B2/en active Active
- 2017-04-20 CN CN202211344339.4A patent/CN116004544A/zh active Pending
- 2017-04-20 CA CA3015371A patent/CA3015371A1/en active Pending
- 2017-04-20 EA EA201892137A patent/EA201892137A1/ru unknown
- 2017-04-20 JP JP2018552822A patent/JP7134868B2/ja active Active
- 2017-04-20 IL IL309065A patent/IL309065A/en unknown
- 2017-04-20 EP EP17723182.6A patent/EP3445780A1/en active Pending
- 2017-04-20 TW TW106113300A patent/TW201803981A/zh unknown
- 2017-04-20 CN CN201780024560.2A patent/CN109071633B/zh active Active
- 2017-04-20 US US16/095,067 patent/US11530277B2/en active Active
- 2017-04-20 SG SG11201807881VA patent/SG11201807881VA/en unknown
- 2017-04-20 MX MX2018012866A patent/MX2018012866A/es unknown
- 2017-04-20 KR KR1020187029371A patent/KR20180134894A/ko not_active Application Discontinuation
-
2022
- 2022-08-31 JP JP2022137796A patent/JP2022164824A/ja active Pending
- 2022-11-10 US US18/054,350 patent/US20230322956A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN109071633B (zh) | 2022-11-18 |
MX2018012866A (es) | 2019-03-11 |
KR20180134894A (ko) | 2018-12-19 |
SG11201807881VA (en) | 2018-10-30 |
AU2017253240A1 (en) | 2018-09-20 |
IL262268B1 (en) | 2024-01-01 |
CA3015371A1 (en) | 2017-10-26 |
IL262268A (en) | 2018-11-29 |
EA201892137A1 (ru) | 2019-03-29 |
AR108295A1 (es) | 2018-08-08 |
TW201803981A (zh) | 2018-02-01 |
JP2019514358A (ja) | 2019-06-06 |
IL262268B2 (en) | 2024-05-01 |
AU2017253240B2 (en) | 2024-07-04 |
US20230322956A1 (en) | 2023-10-12 |
JP7134868B2 (ja) | 2022-09-12 |
KR20210135340A (ko) | 2021-11-12 |
IL309065A (en) | 2024-02-01 |
CN116004544A (zh) | 2023-04-25 |
US20190263937A1 (en) | 2019-08-29 |
WO2017184831A1 (en) | 2017-10-26 |
US11530277B2 (en) | 2022-12-20 |
CN109071633A (zh) | 2018-12-21 |
EP3445780A1 (en) | 2019-02-27 |
BR112018071285A2 (pt) | 2019-02-12 |
JP2022164824A (ja) | 2022-10-27 |
KR102474757B1 (ko) | 2022-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL262268A (en) | Preparations and methods for the preparation of antibodies based on the use of an amplified expression locus | |
IL291711A (en) | Anti-ctla-4 antibodies and methods of using them | |
EP3515478A4 (en) | ANTIBODIES FOR SIGLEC-15 AND METHODS OF USING SAME | |
IL265800A (en) | Anti-lag-3 antibodies and methods of using them | |
IL266918A (en) | Anti-ctla-4 antibodies and methods of using them | |
SG10201912879YA (en) | Anti-sirp-alpha antibodies and methods of use thereof | |
IL262266A (en) | Preparations and methods for preparing antibodies based on the use of expression enhancer loci | |
EP3383430A4 (en) | ANTIBODIES AND METHOD FOR USE THEREOF | |
SG10201912563XA (en) | Anti-tim-3 antibodies and methods of use thereof | |
EP3334765A4 (en) | CHIMERIC ANTIGEN RECEPTORS BASED ON INDIVIDUAL DOMAIN ANTIBODIES AND METHOD FOR USE THEREOF | |
EP3280441A4 (en) | Anti-sortilin antibodies and methods of use thereof | |
EP3105335A4 (en) | Chimeric antigen receptors and methods of making | |
EP3316909A4 (en) | ANTI-NTB-A ANTIBODIES AND ASSOCIATED COMPOSITIONS AND METHODS | |
EP3383917A4 (en) | NOVEL ANTI-CLAUDIN ANTIBODIES AND METHODS OF USE | |
IL265438A (en) | Chimeric antigen receptors and jewelry and methods of using them | |
EP3218370A4 (en) | Methods and compositions for inhibition of bromodomain and extraterminal proteins | |
EP3443076A4 (en) | COMPOSITIONS AND METHODS FOR CHIMERAL ALLOANTigen RECEPTOR T CELLS | |
IL265957A (en) | Anti-c1s antibodies and methods of using them | |
EP3313993A4 (en) | ANTI-APOBEC3 ANTIBODIES AND METHOD OF PREPARATION AND USE | |
EP3538153A4 (en) | ANTI-CD46 ANTIBODIES AND METHOD FOR USE | |
EP3365367A4 (en) | MONOCLONAL ANTIBODIES TO BED TAILS AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
EP3319930A4 (en) | METHOD AND COMPOSITIONS FOR STABILIZING PROTEINS | |
EP3454864A4 (en) | NOVEL ANTI-BMPR1B ANTIBODIES AND METHOD OF USING | |
AU2015901092A0 (en) | PAT-SM3 related antibodies and methods of making and using same | |
AU2014901301A0 (en) | PAT-SM3 related antibodies and methods of making and using same |